20-year MESA analysis finds CT-derived muscle quality predicts COPD more strongly than emphysema-like lung measures. HOUSTON, Texas - August 7, 2026 - HeartLung.AI today announced that the Radiological Society of North America (RSNA) has featured a major research publication demonstrating the potential of artificial intelligence-derived myosteatosis measurements from coronary artery calcium (CAC) CT scans to predict future chronic obstructive pulmonary disease (COPD). The ded

Coronary CT has become one of the most powerful imaging technologies for cardiovascular risk assessment. However, an important clinical question remains: Should Coronary CT Angiography (CCTA) be used routinely to screen asymptomatic individuals, or does Coronary Artery Calcium (CAC) scanning already provide sufficient information for preventive care? This presentation reviews the current evidence comparing CAC scoring and CCTA in primary prevention, examining their predictive

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial Vision 2030 presents HeartLung.AI’s long-term vision for transforming medical imaging into a comprehensive, AI-powered preventive healthcare ecosystem. Rather than generating a diagnostic report alone, the platform is designed to convert a single medical image into a personalized prevention strategy that follows patients throughout their lives. The proposed Preventive Imaging Agentic AI framework integrates multiple in

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual Care The LDCT Mega Trial is an ambitious vision for one of the largest prospective clinical studies ever proposed in artificial intelligence, designed to evaluate whether an Agentic AI-powered preventive imaging ecosystem can improve long-term health outcomes compared with conventional medical care. The proposed randomized trial plans to enroll 100,000 participants across 250 cl

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group AI-CVD is an advanced artificial intelligence platform that transforms routine coronary artery calcium (CAC) and chest CT scans into comprehensive cardiovascular risk assessments by extracting a wide range of imaging biomarkers from a single examination. Rather than relying solely on traditional clinical risk factors, AI-CVD analyzes multiple cardiome

AI-CAC introduces a novel artificial intelligence approach for coronary plaque analysis using non-contrast cardiac CT (CAC) scans, offering the potential to extract plaque characteristics traditionally obtainable only from contrast-enhanced coronary CT angiography (CCTA). Conventional CCTA provides excellent visualization of coronary anatomy but requires intravenous contrast administration and is affected by scanner-, software-, and observer-related variability. AI-CAC addres

Agatston-2.0 is a next-generation artificial intelligence framework developed to enhance cardiovascular risk assessment in individuals with Agatston coronary artery calcium (CAC) scores below 100—a population that represents nearly 75% of individuals undergoing CAC scanning and accounts for a substantial proportion of future coronary heart disease events. Rather than relying solely on conventional calcium scoring, Agatston-2.0 introduces advanced AI-derived biomarkers that an

AutoLung AI is an advanced artificial intelligence platform designed to improve lung cancer detection and long-term risk prediction using a wide range of CT imaging studies—not only dedicated low-dose lung cancer screening CT, but also routine chest CT, coronary artery calcium (CAC) scans, and coronary CT angiography (CCTA). Unlike conventional approaches that primarily focus on pulmonary nodules, AutoLung AI integrates whole-lung imaging biomarkers with nodule-level analysis

Thursday, July 9, 2026 | 2:00-3:00 PM PST LDCT Mega Trial - Preventive Imaging Agentic AI vs Usual CareLIFEMAP Research Group Meeting Objective: To review recent AI-CVD and Agatston-2.0 research progress, discuss the latest LDCT Mega Trial / LIFEMAP study design, evaluate key unresolved protocol questions, introduce LUNGevity as a potential nonprofit administrative and advocacy partner, and begin discussion of funding sources and fundraising plans. 1. Opening Remarks Dr. Mo

Campaign contrasts coronary plaque-centric AI-CCTA marketing with AI-CVD's CAC-based, whole-patient primary prevention approach: one lower-cost, lower-radiation, non-contrast CT scan, 10+ actionable reports, and broader cardiovascular and cardiometabolic risk phenotyping. SAN DIEGO, July 6, 2026 - HeartLung Corporation (HeartLung.AI), a medical AI company transforming CT imaging into preventive care intelligence, today announced the launch of its "Why Pay More and Get Less?"

AI-derived left atrial volume and chamber ratios from CAC scans predicted long-term AF and stroke in MESA and Framingham. HOUSTON, June 18, 2026 - HeartLung.AI today announced that its research article, "AI-Derived LA Volume Index, LA/RA and LA/LV Volume Ratios From Coronary Artery Calcium Scans Predict Long-Term Atrial Fibrillation and Stroke," was featured on the June 2026 episode of the Stroke Alert Podcast, the podcast of Stroke, a journal of the American Heart Associatio

New peer-reviewed study introduces Agatston-2.0, led by Morteza Naghavi, MD, with Arthur S. Agatston, MD, the originator of the original Agatston score, and leading cardiovascular imaging and prevention experts. HOUSTON, TX, June 2026 — HeartLung Corporation today announced the publication of a landmark peer-reviewed study introducing Agatston-2.0, a next-generation artificial intelligence-based coronary artery calcium scoring method designed to modernize one of the most infl

HOUSTON, TX, May 18, 2026 - HeartLung Corporation announced the publication of a new study in the American Journal of Preventive Cardiology titled “Comparing Incidence of Heart Failure in Individuals with Enlarged Cardiac Chambers versus Diabetes.” The study demonstrates that HeartLung’s AI-CVD AutoChamber module can opportunistically identify left atrial enlargement, left ventricular enlargement, and increased left ventricular mass from routine coronary artery calcium scans,

Accepted studies showcase HeartLung.AI’s leadership in AI-CVD, opportunistic CT screening, Agatston 2.0, chamber volumetry, and preventive cardiology. HOUSTON, Texas, 05/11/2026 – HeartLung.AI today announced that 10 scientific abstracts have been accepted for presentation at ESC Congress 2026, the annual meeting of the European Society of Cardiology. The accepted studies showcase HeartLung.AI’s growing leadership in AI–enabled cardiovascular imaging and preventive cardiology

New intellectual property milestones strengthen HeartLung’s leadership in AI–enabled preventive CT imaging and coronary inflammation assessment HOUSTON, TX, UNITED STATES, May 3, 2026 /EINPresswire.com/ -- HeartLung Corporation, a medical technology company advancing AI–enabled, CT–based opportunistic screening and early disease detection, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,620,494, titled “Predicting adverse healt

CMS Code G0680 opens doors to AI-enabled opportunistic detection of patients with silent coronary artery disease who are unaware of their risk of a future heart attack. HOUSTON, April 7, 2026 -- HeartLung AI today welcomed CMS’s establishment of HCPCS code G0680 in the April 2026 Hospital Outpatient Prospective Payment System update, effective April 1, 2026, for algorithmic analysis of coronary artery calcium (CAC) and/or aortic valve calcification from chest CT with report.